Luteinizing hormone-releasing hormone analogues in early breast cancer: Updated status of ongoing clinical trials

British Journal of Cancer

Volumn 78, Issue SUPPL. 4, 1998, Pages 9-11

  Kaufmann, M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Clinical trials; Early breast cancer; Endocrine manipulation; Goserelin; Luteinizing hormone releasing hormone analogues

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; METHOTREXATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; FEMALE; HUMAN; META ANALYSIS; PRIORITY JOURNAL;

EID: 0031670887     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.755     Document Type: Review

References (11)

1. Blamey RW, Jonat W, Kaufmann M, Raffaele Bianco A and Namer M (1992) Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 28A: 810-814
2. Blamey RW, Jonat W, Kaufmann M, Bianco AR and Namer M (1993) Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer (letter). Eur J Cancer 29A: 1498
3. Blamey RW, Jonat W, Kaufmann M, Schumacher M, Cuzick J and Lee D (1996) Temporary ovarian ablation with 'Zoladex' (goserelin acetate) in premenopausal women with early breast cancer (abstract). In Proceedings of the Ninth International Congress on Breast Diseases. 39th Annual Clinical Conference of the University of Texas MD Anderson Cancer Center, Houston, 28 April-2 May 1996, p. 102
4. Cheson BD (1991) Clinical trials referral resource. Oncology (New York) 5(7): 115-131
5. Early Breast Cancer Trialists' Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348: 1189-1196
6. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, Lindtner J, Collins J, Senn HJ, Brunner KW and Galligioni E (1994) Present and future projects of the International Breast Cancer Study Group. Cancer 74(suppl. 3): 1139-1149
7. Jonat W, Kaufmann M, Blamey R, Sheldon T (1998) The 'ZEBRA' study: 'Zoladex' (goserelin) vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less (abstract 107). Eur J Cancer 34(suppl. 1): S41
8. Kaufmann M, Jonat W, Kleeberg U, Eiermann W, J'anicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK and Schmid H (1989) Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7: 1113-1119
9. Kaufmann M, Jonat W, Schachner-Wünschmann E, on behalf of the Cooperative German Zoladex Study Group (1991 ) The depot GnRH analogue goserelin (Zoladex) in the treatment of pre-menopausal patients with metastatic breast cancer - a 5-year experience and further endocrine therapies. Onkologie 14: 22-30
10. Simpson KL (1991) An LHRH analogue in early breast cancer: clinical trial programme. In Current Controversies in the Treatment of Breast Cancer. Proceedings of the First Nottingham International Breast Cancer Meeting, 22-28 September 1990. Blamey RW (ed.). The Parthenon Publishing Group, New Jersey, pp. 51-55
11. Wells UM, Moritz S, Riley DL, Houghton J, Baum M, Odling-Smee W on behalf of the Current Trials Working Party of the CRC Breast Cancer Trials Group (1997) Preliminary report: the CRC adjuvant breast trial for patients under the age of 50 (abstract 0-109). Fifth Nottingham International Breast Cancer Conference, Nottingham, 17-19 September 1997. Breast 6: 255